antibody-related businesses, we have been developing business in close collaboration with our partner partner MorphoSys. In recent years, antibody drugs have been able to specifically attack proteins that become disease-related factors by utilizing the inherent property of antibodies that bind only to target cells such as cancer cells, and have a breakthrough with fewer side effects. Because of the therapeutic effects, development competition is occurring worldwide. We use fully artificial recombinant human antibody production technology introduced from Germany's MorphoSys to promote antibody drug target search business through joint research with other companies and other organizations, and licensing to Japanese bio-drug discovery companies. We are actively working to further accelerate biopharmaceutical research and development. Gene Frontier has expanded its business domains that lead to the acceleration of biopharmaceuticals including antibody drugs, and is also developing its own technologies. In the future, with the support of Kaneka, we will accelerate research and development and business development, and aim for further growth toward the world. Gene Frontier shares Kaneka's corporate vision, “To be more surprised, to Mirai.” And will continue to provide unique technologies and services for the development of innovative medicines and diagnostics. As a partner, we will contribute to medical treatment in the 21st century.